Explanation
Empagliftozin
Empaqliflozinisan SGLT-2 inhibitor. whichueadstorenatexcretiom
glucoseandhaspositiveeffects on
HbAlcand is associated withminor,2-3loss in weight on average). overa6 month period.talso hasa
positiveimpactoncardiovascular mortality as evidenced bvtheEMPA-REG study. Giventhis patiemtspositive
historv withrespecttoischaemcheartdisease.and sianificantobesitv.tisthereforethemostaopropriate
option.
@1MINENDOCRINE
